--- title: "Zai Lab Sets February 26 Board Meeting to Approve and Release 2025 Annual Results" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275665019.md" description: "Zai Lab Ltd has scheduled a board meeting for February 26, 2026, to approve its audited financial results for the year ended December 31, 2025, under U.S. GAAP. If approved, the results will be published on the same day, followed by a teleconference for the investment community. The company will also issue a Hong Kong-compliant annual results announcement by March 31, 2026. The latest analyst rating for Zai Lab (HK:9688) is a Hold with a price target of HK$18.00." datetime: "2026-02-11T13:39:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275665019.md) - [en](https://longbridge.com/en/news/275665019.md) - [zh-HK](https://longbridge.com/zh-HK/news/275665019.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275665019.md) | [繁體中文](https://longbridge.com/zh-HK/news/275665019.md) # Zai Lab Sets February 26 Board Meeting to Approve and Release 2025 Annual Results ### Valentine's Day Sale - 70% Off - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Zai Lab Ltd ( (HK:9688) ) has provided an announcement. Zai Lab Limited has scheduled a board meeting for February 26, 2026 to consider and approve its audited financial results for the year ended December 31, 2025, prepared under U.S. GAAP and U.S. SEC requirements. If approved, the company will publish the 2025 annual results on the Hong Kong exchange website and its own investor relations site the same day. Following the release, Zai Lab’s management will host a teleconference and webcast on February 26, 2026 to discuss the results and take questions from the investment community. The company also plans to issue its Hong Kong-compliant annual results announcement by March 31, 2026, including a reconciliation from U.S. GAAP to IFRS, underscoring its commitment to transparency for cross-border shareholders. The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page. **More about Zai Lab Ltd** Zai Lab Limited is a biopharmaceutical company listed in Hong Kong that develops and commercializes innovative medicines, with its financial reporting prepared under U.S. GAAP and subject to U.S. SEC rules. The company is also subject to Hong Kong Listing Rules, reflecting its dual-market regulatory and investor base across the U.S. and Hong Kong markets. **Average Trading Volume:** 10,552,263 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$15.26B Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page. ### 相关股票 - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [ZAI LAB (09688.HK)](https://longbridge.com/zh-CN/quote/09688.HK.md) - [Zai Lab (ZLAB.US)](https://longbridge.com/zh-CN/quote/ZLAB.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) ## 相关资讯与研究 - [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-CN/news/278776483.md) - [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-CN/news/278542482.md) - [Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting](https://longbridge.com/zh-CN/news/278091205.md) - [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-CN/news/278880252.md) - [Century Therapeutics 2025 net loss narrows beating estimates](https://longbridge.com/zh-CN/news/278880556.md)